VOGX logo

VOGX Vogenx Inc.

NASDAQ · Biotechnology · Healthcare

$16.67
-2.48 (-12.95%)

Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the …

Market Cap: $247.63Mwww.vogenx.com

Price

No data yet.

Social Signal Score

33
5d
—
30d
—
60d
30
2 mentions
—
90d
37
3 mentions
—
news: 3

Revenue

$0.00
$0.00
Dec 31Sep 30

Analyst Estimates

FY2026
$-0.61
$-0.69–$-0.52
1 analysts
FY2027
$-1.52
$-1.52–$-1.52
1 analysts
FY2028
$-3.91
$-3.91–$-3.91
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
James Green
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
0.00
Country
US
www.vogenx.com